ESC Professional Premium Access

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

Congress Presentation

About the speaker

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)
1 presentation
0 follower

2 more presentations in this session

State-of-the-art lecture in lipid lowering therapy and the atheroma .

Speaker: Professor S. Nicholls (Melbourne, AU)


Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial

Speaker: Doctor K. Koskinas (Bern, CH)


Access the full session

Lipid-lowering therapy and the atheroma

Speakers: Doctor S. Goodman, Professor S. Nicholls, Doctor K. Koskinas

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb